Cargando…

Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer

Human epidermal growth factor receptor 2–targeted (HER2-targeted) therapy is the mainstay of treatment for HER2(+) breast cancer. However, the proteolytic cleavage of HER2, or HER2 shedding, induces the release of the target epitope at the ectodomain (ECD) and the generation of a constitutively acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Muwen, Li, Kong, Lingzhi, Huang, Shumei, He, Lixin, Liu, Pian, Mo, Shuang, Lu, Xiuqing, Lin, Xi, Xiao, Yunyun, Shi, Dongni, Huang, Xinjian, Chen, Boyu, Chen, Xiangfu, Ouyang, Ying, Lin, Chuyong, Song, Libing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348774/ https://www.ncbi.nlm.nih.gov/pubmed/37463446 http://dx.doi.org/10.1172/JCI164428

Ejemplares similares

BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate
por: Huang, Xinjian, et al.
Publicado: (2023)

Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer
por: Wang, Meng, et al.
Publicado: (2021)

HOMER3 facilitates growth factor-mediated β-Catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer
por: Liu, Qinghua, et al.
Publicado: (2021)

Protein phosphatase 1 regulatory inhibitor subunit 14C promotes triple‐negative breast cancer progression via sustaining inactive glycogen synthase kinase 3 beta
por: Jian, Yunting, et al.
Publicado: (2022)

HMMR promotes peritoneal implantation of gastric cancer by increasing cell–cell interactions
por: Yang, Muwen, et al.
Publicado: (2022)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2019)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2022)

Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
por: Jian, Yunting, et al.
Publicado: (2021)

Characterisation of a novel cardiac phenotype in patients with GFPT1 or DPAGT1 mutations
por: Lewis, Andrew, et al.
Publicado: (2014)

Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design
por: Dong, Yin Yao, et al.
Publicado: (2018)

DPAGT1‐Mediated Protein N‐Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice
por: Li, Hui, et al.
Publicado: (2020)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer
por: Jiang, Lili, et al.
Publicado: (2020)

A Dpagt1 Missense Variant Causes Degenerative Retinopathy without Myasthenic Syndrome in Mice
por: Hyde, Lillian F., et al.
Publicado: (2022)

DPAGT1-CDG: Functional analysis of disease-causing pathogenic mutations and role of endoplasmic reticulum stress
por: Yuste-Checa, Patricia, et al.
Publicado: (2017)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
por: Mitachi, Katsuhiko, et al.
Publicado: (2019)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
por: Lei, Lei, et al.
Publicado: (2019)

A genome-wide CRISPR screen identifies DPM1 as a modifier of DPAGT1 deficiency and ER stress
por: Dalton, Hans M., et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report
por: Huang, Jiayi, et al.
Publicado: (2022)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Pre-Implantation Genetic Testing for Monogenic Disorders (PGT-M) in A Family with A Novel Mutation in DPAGT1 Gene
por: Tabatabaei, Zahra, et al.
Publicado: (2021)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Protein N-glycosylation in oral cancer: Dysregulated cellular networks among DPAGT1, E-cadherin adhesion and canonical Wnt signaling
por: Varelas, Xaralabos, et al.
Publicado: (2014)

Clinical features in a large Iranian family with a limb-girdle congenital myasthenic syndrome due to a mutation in DPAGT1
por: Basiri, Keivan, et al.
Publicado: (2013)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Intermolecular Interactions of Nucleoside Antibiotic Tunicamycin with On-Target MraY(CB)-TUN and Off-Target DPAGT1-TUN in the Active Sites Delineated by Quantum Mechanics/Molecular Mechanics Calculations
por: Astani, Elahe K., et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9cdoh4jrdp4ua4gfolohmjdm4p